Rigel Pharmaceuticals says REZLIDHIA now available in U.S. by prescription

Rigel Pharmaceuticals announced that REZLIDHIA capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test. REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells. REZLIDHIA was approved by the U.S. FDA on December 1, 2022.